Abstract:Background Severe hindlimb ischemia is a chronic disease with poor prognosis that can lead to amputation or even death. This study aimed to assess the therapeutic effect of liraglutide on hind‐limb ischemia in type 2 diabetic mice and to elucidate the underlying mechanism. Methods and Results Blood flow reperfusion and capillary densities after treatment with liraglutide or vehicle were evaluated in a mouse model of lower‐limb ischemia in a normal background or a background of streptozotocin‐induced diabetes. The proliferation, migration, and tube formation of human umbilical vein endothelial cells were analyzed in vitro upon treatment with liraglutide under normal‐glucose and high‐glucose conditions. Levels of phospho‐Akt, phospho‐endothelial nitric oxide synthase, and phospho‐extracellular signal‐related kinases 1 and 2 under different conditions in human umbilical vein endothelial cells and in ischemic muscle were determined by western blotting. Liraglutide significantly improved perfusion recovery and capillary density in both nondiabetic and diabetic mice. Liraglutide also promoted, in a concentration‐dependent manner, the proliferation, migration, and tube formation of normal glucose– and high glucose–treated human umbilical vein endothelial cells, as well as the phosphorylation of Akt, endothelial nitric oxide synthase, and extracellular signal‐related kinases 1 and 2 both in vitro and in vivo. The liraglutide antagonist exendin (9–39) reversed the promoting effects of liraglutide on human umbilical vein endothelial cell functions. Furthermore, exendin (9–39), LY294002, and PD98059 blocked the liraglutide‐induced activation of Akt/endothelial nitric oxide synthase and extracellular signal‐related kinases 1 and 2 signaling pathways. Conclusions These studies identified a novel role of liraglutide in modulating ischemia‐induced angiogenesis, possibly through effects on endothelial cell function and activation of Akt/endothelial nitric oxide synthase and extracellular signal‐related kinases 1 and 2 signaling, and suggested the glucagon‐like peptide‐1 receptor may be an important therapeutic target in diabetic hind‐limb ischemia.

Liraglutide Prevents High Glucose Induced HUVECs Dysfunction Via Inhibition of PINK1/Parkin-dependent Mitophagy

The GLP‐1 Receptor Agonist Liraglutide Protects Against Oxidized LDL‐induced Endothelial Inflammation and Dysfunction Via KLF2

Liraglutide prevents cellular senescence in human retinal endothelial cells (HRECs) mediated by SIRT1: an implication in diabetes retinopathy

Liraglutide Improves the Angiogenic Capability of EPC and Promotes Ischemic Angiogenesis in Mice under Diabetic Conditions through an Nrf2-Dependent Mechanism

A Novel Angiogenesis Role of GLP-1(32-36) to Rescue Diabetic Ischemic Lower Limbs Via GLP-1R-Dependent Glycolysis

Liraglutide Protects High-Glucose-stimulated Fibroblasts by Activating the CD36-JNK-AP1 Pathway to Downregulate P4HA1

Glucagon-Like Peptide-1 Analogue Liraglutide Ameliorates Atherogenesis Via Inhibiting Advanced Glycation End Product-Induced Receptor for Advanced Glycosylation End Product Expression in Apolipoprotein-E Deficient Mice

[The Renal Protective Effect and Mechanism of Liraglutide in Diabetic Mice Induced by High-Fat Diet].

Liraglutide ameliorates high glucose-induced vascular endothelial injury through TRIB3/NF-κB signaling pathway

Protective effect of Liraglutide on diabetic retinal neurodegeneration via inhibiting oxidative stress and endoplasmic reticulum stress

Liraglutide Inhibits Endothelial-to-Mesenchymal Transition and Attenuates Neointima Formation after Endovascular Injury in Streptozotocin-Induced Diabetic Mice

Glucagon-like Peptide-1 Receptor Agonist Liraglutide Inhibits Endothelin-1 in Endothelial Cell by Repressing Nuclear Factor-Kappa B Activation

Anagliptin Ameliorates High Glucose- Induced Endothelial Dysfunction Via Suppression of NLRP3 Inflammasome Activation Mediated by SIRT1

Protective Action of Liraglutide in Beta Cells Under Lipotoxic Stress Via PI3K/Akt/FoxO1 Pathway

Liraglutide Alleviates Myocardial Ischemia‒reperfusion Injury in Diabetic Mice

Liraglutide Reduces Hepatic Glucolipotoxicity‑induced Liver Cell Apoptosis Through NRF2 Signaling in Zucker Diabetic Fatty Rats

Liraglutide Promotes the Angiogenic Ability of Human Umbilical Vein Endothelial Cells Through the JAK2/STAT3 Signaling Pathway

Liraglutide Reduces Coronary Endothelial Cells No-Reflow Damage Through Activating MAPK/ERK Signaling Pathway.

Liraglutide Accelerates Ischemia‐Induced Angiogenesis in a Murine Diabetic Model

Liraglutide Ameliorates Palmitate-Induced Endothelial Dysfunction Through Activating AMPK and Reversing Leptin Resistance.

Glucagon-Like Peptide 1 Protects against Hyperglycemic-Induced Endothelial-to-Mesenchymal Transition and Improves Myocardial Dysfunction by Suppressing Poly(ADP-Ribose) Polymerase 1 Activity